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Algae against malnutrition
Achieving an adequate nutrition is a growing global con-
cern with the increase in world population. Therefore,
cost-effective sources of nutrients that can easy and
rapidly produce large amounts of products of high nutri-
tional value are needed. Algae can provide a signiﬁcant
source of a diverse number of essential nutrients to sup-
port human health. Algae are ubiquitous throughout the
world and have persisted and thrived in numerous types
of environments. Algae are a diverse group of photosyn-
thetic organisms both unicellular (microalgae) and multi-
cellular (macroalgae) that have the ability to grow
rapidly, efﬁciently use light energy, ﬁx atmospheric CO2,
and produce more biomass per hectare than vascular
plants.
This review assesses the properties of microalgae that
are microscopic photosynthetic organisms present in
both marine and freshwater environments. The term
microalgae, in applied phycology, usually includes the
microscopic algae sensu stricto and the photosynthetic
bacteria (i.e. cyanobacteria), formerly known as
Cyanophyceae. The cell structure is eukaryotic in
microalgae and prokaryotic in cyanobacteria, but in
terms of biomass, they are both considered as a poten-
tial source of energy, fuel, food and other many interest-
ing commercial products. The most abundant microalgal
classes are Cyanophyceae (blue-green algae), Chloro-
phyceae (green algae), Bacillariophyceae (including the
diatoms) and Chrysophyceae (including golden algae).
Currently, many microalgae are acquiring increasing
biotechnological interest because they can produce a
number of nutraceutical compounds. These molecules
can be deﬁned as nutrients from food products that not
only supplement the diet but also facilitate the prevention
or treatment of a disease and/or disorder. Recent articles
review the state of the art on the biotechnological pro-
duction and use of microalgae (Chew et al., 2017;
Odjadjare et al., 2017), but specially as food and feed
(Yaakob et al., 2014; Liu and Chen, 2016; Bleakley and
Hayes, 2017), and nutraceuticals (Nicoletti, 2016; Yan
et al., 2016; Bilal et al., 2017; Wells et al., 2017). The
aim of this article was to provide an overview of the cur-
rent challenges on the use of microalgae as food, feed
and nutraceutical products.
Old foods and new medicines
Microalgae have been used as a human food source or
nutritional supplements for hundreds of years. Aztecs
used the cyanobacterium Spirulina (Arthrospira platensis,
Arthrospira maxima) from Lake Texcoco (Mexico) circa
AD 1300. Spanish chroniclers described local ﬁshermen
collecting blue-green masses from the lakes that were
prepared as a dry cake, known as ‘tecuitlatl’. For
centuries, the population in Chad has been harvesting
Spirulina (known as ‘dihe’) from Lake Kossorom at the
north-east fringe of Lake Chad and using it for food on a
daily basis. Nostoc, ﬁlamentous cyanobacteria, has been
also widely used as food. The species N. commune,
N. ﬂagelliforme and N. punctiforme are traditionally con-
sumed in China, Mongolia, Tartaria and South America
(known as ‘fa cai’ and ‘lakeplum’). In Japan, another edi-
ble cyanobacterium Aphanotheca sacrum (formerly Phyl-
loderma sacrum) is considered a special delicacy known
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as ‘suizenji-nori’. The ﬁlamentous green algae Spirogyra
and Oedogonium are also used as a dietary
component in Burma, Thailand, Vietnam and India.
Despite this background, the modern era of microalgal
and cyanobacterial biotechnological developments
began in the early 1940s and gained momentum with
the ﬁrst Algal Mass-Culture Symposium that was held at
Stanford University in 1952. Since then, numerous tech-
nologies and approaches for mass controlled cultivation
of microalgae (e.g. open ponds, specialized photobiore-
actors) have been suggested for their commercial
exploitation apart from being harvested from natural
environments. Moreover, Spirulina was declared by the
United Nations World Food Conference of 1974 as the
best food for the future, and United Nations World Health
Organization (WHO) stated that Spirulina represents an
interesting food for multiple reasons, for example, it is
rich in iron and protein and is able to be administered to
children without any risk (Geneva, Switzerland June
8Th, 1993). During the sixtieth session of the United
Nations General Assembly (Second Committee, Agenda
item 52), IIMSAM (International institution for the use of
microalgae Spirulina against malnutrition) initiated a
revised draft resolution on the ‘Use of Spirulina to
combat hunger and malnutrition and help achieve sus-
tainable development’. As a follow-up on this resolution,
the United Nations Food and Agriculture Organization
(FAO) prepared a draft position on Spirulina that was
presented in 2008 (FAO, 2011). Thus, microalgae can
be an alternative to achieve food of high quality with a
low environmental impact, because they can be culti-
vated in non-cultivable lands.
Nowadays, Chlorella and Spirulina are widely commer-
cialized in health food stores gaining worldwide popular-
ity because they are one of the most nutritious foods
known to man. These microalgae are also used to feed
many types of animals (e.g. cats, dogs, aquarium ﬁsh,
ornamental birds, horses, poultry, cows and breeding
bulls). Moreover, other microalgae such as Tetraselmis,
Isochrysis, Pavlova, Phaeodactylum, Chaetoceros, Nan-
nochloropsis, Skeletonema and Thalassiosira are also
used as feeds in aquaculture (Gouveia et al., 2008).
However, microalgae are also potential sources of valu-
able bioactive compounds with a wide application as
nutraceuticals. The nutraceuticals that can be extracted
from microalgae are very abundant and diverse
(Table 1) and have been proposed to treat a large num-
ber of diseases; nevertheless, some of these properties
must be still conﬁrmed by solid clinical trials.
Carotenoids are in general richly coloured molecules
consisting of a class of more than 600 naturally occur-
ring organic pigments synthesized by plants, algae and
bacteria which play different physiological roles and
because of that they offer huge nutraceutical values.
b-Carotene is used as a food colouring as well as to
improve the health and fertility of grain-fed cattle. Astax-
anthin is well known to have powerful antioxidant and
anti-inﬂammatory activities capable of preventing or
reducing protein degradation, macular degeneration,
rheumatoid arthritis, cardiovascular diseases, neurode-
generative diseases, such as Parkinson’s, and
cancers. Lutein, zeaxanthin and b-carotene prevent pre-
menopausal breast cancer, while cryptoxanthin and
a-carotene prevent cervical cancer. Moreover, fucoxan-
thin has antiobesity and anticancer activities. Chlorophyll
is a photosynthetic pigment found in all photoautotrophic
organisms and has been shown to stimulate liver func-
tion recovery and increase bile secretion (Bishop and
Zubeck, 2012). It also repairs cells, increases haemoglo-
bin in blood and promotes rapid cell growth. Chlorophyll
is reported to have antimutagenic, anticarcinogenic and
antioxidant activities. Traditionally, is used in the food
industry as a colorant due to the increasing consumer
demands for natural foods.
Phycobiliproteins are hydrophilic proteins bonded to
the photosynthetic pigments phycobilins, mainly found in
cyanobacteria and some red algae (Sonani et al., 2016).
Nowadays, one of the main uses of Spirulina is for the
extraction of phycocyanin that is exploited for many pur-
poses (e.g. natural dyes, ﬂuorescent agents/markers,
cosmetics) but as nutraceutical it has been commercial-
ized as antioxidant, anti-inﬂammatory, neuroprotective or
hepatoprotective agent.
PUFAs (polyunsaturated fatty acids) contain three or
more double bonds on a fatty acid skeletal chain con-
taining 18 or more carbon atoms. In particular, n-3
PUFAs have been shown to be effective in preventing or
treating several diseases (e.g. cardiovascular disorders,
cancer, type 2 diabetes, inﬂammatory bowel disorders,
asthma, arthritis, kidney and skin disorders, depression
and schizophrenia).These compounds are now mainly
derived from ﬁsh oil but due to several concerns (e.g.
overexploitation of marine reserves, accumulation of
toxic compounds in ﬁshes, peculiar smell, unpleasant
taste, oxidative instability), there is an increasing interest
in using microalgae as potential alternative source of
PUFAs.
Many microalgae are producers of structurally diverse
exopolysaccharides (EPS) that are widely used in the
food industry as thickeners and gelling additives (Liu
et al., 2016). EPS have been shown to have multiple
pharmaceutical activities (e.g. antioxidant, antitumor,
antihyperlipidemia, antibacterial and anticoagulant
activities).
Other bioactive compounds of interest that can be
obtained from microalgae are sterols (Luo et al., 2015).
This family of compounds has become well known for
their ability to reduce LDL cholesterol and promote
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cardiovascular health. Moreover, sterols have been
reported to be involved in anti-inﬂammatory and
antiatherogenicity, anticancer and antioxidative activities
and can provide protection against nervous system
disorders, such as autoimmune encephalomyelitis, amy-
otrophic lateral sclerosis or Alzheimer’s disease.
Several microalgae have total phenolic contents that
are similar to or even higher than several popular fruits
Table 1. Microalgae products.
Products Microalgae References
Food Chlorella, Spirulina, Odontella auriata, Tetraselmis
chuii Aphanizomenon ﬂosaquae, Nostoc, A. sacrum,
Spirogyra, Oedogonium
Gantar and Svircev (2008), Liu and Chen (2016)
and Bleakley and Hayes (2017)
Feed Chlorella, Spirulina, Tetraselmis, Isochrysis, Pavlova,
Phaeodactylum, Chaetoceros, Nannochloropsis,
Skeletonema, Thalassiosira
Gouveia et al. (2008) and Yaakob et al. (2014)
Vitamins & carotenoids
Vitamin B12 Chlorella, Spirulina Begum et al. (2016), Henrıquez et al. (2016)
and Sun et al. (2016)Vitamin E Porphyridum cruentum
b-carotene D. salina, Haematococcus pluvialis, Synechococcus,
Nanocloropsis gaditana
a-carotene Chlorella
Astaxanthin D. salina, H. pluvialis, Chlorella
Lutein Murellopsis sp., Chlorella, Scenedesmus almeriensis,
Auxenochlorella protothecoides
Zeaxanthin D. salina, Chlorella, Synechococcus, N. gaditana
Canthaxanthin Scenedesmus komarekii, D. salina, Chlorella
Fucoxanthin Phaeodactyllum tricornutum
Phytoene D. salina
Phytoﬂuene D. salina
Violaxanthin Chlorella, Synechococcus, N. gaditana
Antheraxanthin Chlorella
Echinenone Botrycoccus braunii
Cryptoxanthin D. salina
Phycobiliproteins
Phycocyanin Spirulina Sonani et al. (2016)
Phycoerythrin Porphyridium
Allophycocyanin Spirulina
Chlorophyll
Chlorophyll A A. ﬂosaquae Bishop and Zubeck (2012)
PUFAs
Eicosapentaenoic acid (EPA) Phaeodactylum tricornutum, Monodus subterraneus,
P. cruentum, Chaetoceros calcitrans, Nannochloropsis,
Schizochytrium
Pereira et al. (2012) and Adarme-Vega
et al. (2014)
Docosahexaenoic acid (DHA) Crypthecodinium cohnii, Isochrysis galbana, Pavlova
salina, Schizochytrium
Linoleic acid D. salina
c-linolenic acid Spirulina
Oleic acid D. salina, Spirulina
Lauric acid Spirulina
Polysaccharides
Sulphated polysaccharides Porphiridium spp. Delattre et al. (2016) and Xiao and Zheng (2016)
Nostoﬂan Nostoc ﬂagelliforme
Sterols
Brassicasterol, sitosterol,
and stigmasterol
D. salina, Dunaliella tertiolecta Luo et al. (2015)
Phenolic & volatile
compounds
Phenolic compounds Chlorella, Nostoc, Anabaena, Tolypothrix,
Chlamydomonas
Plaza et al. (2010) and de Morais et al. (2015)
b-Cyclocitral D. salina
a- and b-Ionone D. salina
Neophytadiene D. salina
Phytol D. salina
Pentadecane Synechocystis sp.
Heptadecane Spirulina
Extracts
Total Chlorella, Chlamydomonas Nakashima et al. (2009)
Lipids Nostoc, Ulkenia
Carotenoids Chlorella
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and vegetables (de Morais et al., 2015). Their biological
functions are very diverse highlighting antioxidant, anti-
inﬂammatory, antimicrobial activities and slow the pro-
gression of certain cancers and reduce the risks of car-
diovascular disease, neurodegenerative diseases and
diabetes.
Finally, microalgae have been reported to be a source
of volatile compounds having antimicrobial activity (Plaza
et al., 2010).
Concerns associated with consumption of
microalgae
Although the nutritional value of microalgae has been
well documented, their digestibility and overall nutritional
value depend not only on the genetic traits of individual
strains but also on the technological processes used for
biomass production. Some studies mention the taste,
texture, colour and odour of microalgal biomass as
potential bottlenecks, while other indicate that microal-
gae have the desired taste, texture and odour. These
properties are therefore relevant issues to be considered
in the development of food products or ingredients
based on microalgae.
One of the limiting factors of using large quantities of
microalgae for human consumption is the high content of
nucleic acids that are metabolized to uric acid and might
result in adverse health effects, such as gout or kidney
stones (Gantar and Svircev, 2008).
Cyanobacterial biomass, besides being produced in
controlled conditions, is also harvested for commercial
purposes from natural environments (e.g. Klamath Falls
Lake (USA) and Lake Chad (Chad)) and although natu-
ral habitats are advantageous with respect to using nutri-
ent sources naturally present in those lakes, the quality
of this biomass is less consistent compared to that pro-
duced in controlled systems and requires frequent and
extensive monitoring.
Some cyanobacteria can produce potent hepatotoxins
and neurotoxins, and thus, when microalgae are grown
in open basins or harvested from natural lakes, there is
a risk of biomass becoming contaminated with alien toxic
cyanobacteria and other biological and non-biological
contaminants (Grobbelaar, 2003).
Engineering microalgae
Several microalgae (e.g. Synechococcus, Synechocystis,
Anabaena, Chlamydomonas reinhardtii, Nanocloropsis
gaditana, Ostreococcus tauri, Porphyridium tricornutum)
are currently established for genetic engineering
approaches (Doron et al., 2016). Curiously, Spirulina has
proved to be extremely recalcitrant to transformation.
Genetic modiﬁcation of eukaryotic microalgae and
cyanobacteria is now mainly studied in the laboratory
because for industrial production, the process should be
scaled up and applied outdoors. Under contained condi-
tions genetically modiﬁed organisms (GMOs) can be cul-
tured and processed in such a way that protective
measures can be used to prevent their direct contact with
the environment; however, for industrial production out-
doors, it will be impossible to work under such conditions
and the current legislations hinder the implementation of
these processes. In this sense, CRISPR/Cas9 technology
has been recently used to efﬁciently generate stable tar-
geted gene mutations in microalgae, using P. tricornutum
(Nymark et al., 2016) and Nannocloropsis as model organ-
isms (Wang et al., 2016). Whether organisms modiﬁed
using editing technologies will be considered as GMOs is
now under discussion in many developed countries.
The metabolic optimization of microalgae as biocata-
lysts requires a systems level understanding of their
metabolic and physiological processes and genome-
scale metabolic network reconstructions may be essen-
tial in achieving these goals and several genome-scale
metabolic models of microalgae are already available
(Gudmundsson and Nogales, 2015).
Although metabolic engineering and synthetic biology
of microalgae are promising approaches to increasing
the production of nutraceuticals under contained condi-
tions (Gimpel et al., 2015), there are still very few exam-
ples of advances in this matter, for example PUFAs
(Hamilton et al., 2016) and carotenoids (Wang et al.,
2014).
Challenges for developing large-scale
photobioreactors
Natural waters (lakes, lagoons, ponds) or artiﬁcial ponds
have been used in the past to grow microalgae. Open-
air systems depend on natural light for illumination, and
although they are inexpensive to install and run, they
suffer from many problems (e.g. cultures are not axenic;
predators can damage the culture; weather variability
hampers a proper control of the system). The species
that are currently being cultured in open ponds are extre-
mophiles capable of growing in a highly selective envi-
ronment (high pH, salinity or temperature) to preclude
the growth of contaminants (Xu et al., 2009).
The future of microalgal biotechnology depends on the
development of large-scale photobioreactors (PBRs)
capable of operating under deﬁned optimal conditions
with minimal contamination risks (Wang et al., 2012).
Compared with open-air systems, closed systems can
circumvent most of their problems, but a development of
more economical, and efﬁcient closed culturing systems
are needed. Several types of closed PBRs have been
designed so far including tubulars, plastic bags, ﬂat
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plates, airlift and bubble columns, stirred tank reactors or
even building-window reactors (Xu et al., 2009; Enzing
et al., 2014). In all cases, an efﬁcient use of light is a
major constraint and makes the scale-up difﬁcult. Thus,
new developments in lighting and its control are needed
to make closed culture systems competitive. In this
sense, irradiance oriented, optical ﬁbres or diodes pro-
viding internal illumination have been used to enhance
light intensity (Glemser et al., 2016; Sun et al., 2016).
Designing surfaces with proper materials, functional
groups or surface coatings, to prevent microalgal adhe-
sion is also essential for solving the typical biofouling
problems of PBRs (Zeriouh et al., 2017).
On the other hand, scale-up methodologies have to be
improved for achieving efﬁcient light provisions, minimal
carbon dioxide losses, and efﬁcient mixing and removal
of generated oxygen (Gupta et al., 2015). Microalgal pro-
cesses have similarities to traditional bioprocesses but
demand unique monitoring requirements (Havlik et al.,
2016). Modularization and computational ﬂuid dynamics
have been used to optimize the structural conﬁgurations
of PBRs for scale-up (Xu et al., 2009). Continuous cul-
ture cultivation and the development of PBRs for life
support systems in the space add new challenges in this
ﬁeld.
Finally, in spite of the problems found to develop
large-scale closed systems, it is worth to mention that
although closed reactors could be too small for some
products like biofuels, they can be reasonable for high
value-added products like nutraceuticals. Moreover, con-
tained PBRs allow the production of nutraceuticals by
using recombinant microalgae.
Safety and regulatory issues
As stated above, food safety is a relevant aspect to be
considered in microalgae technology, especially for pro-
duction in open-air systems (Enzing et al., 2014). Thus,
the regulations on the utilization and production of
microalgal products are taken into account in developed
countries by their regulatory bodies.
There are two EU regulations that most closely affect
production and commercialization of microalgae-based
products for food and feed (Vigani et al., 2015), that is,
the Regulation on Food Safety and the Regulation on
Novel Food and Novel Food Ingredients. Regulation
about GMOs for food and feed is excluded of the list
because, at this moment, there are not recombinant
microalgae at commercial phase. In 2002, the European
Parliament and the Council adopted General Food Law
Regulation (EC No 178/2002) laying down the general
principles and requirements of food law. It sets out a
framework for the development of food and feed legisla-
tion both at EU and national levels. It also sets up an
independent agency responsible for scientiﬁc advice and
support, the European Food Safety Authority (EFSA).
Novel Food is deﬁned as food that has not been con-
sumed to a signiﬁcant degree by humans in the EU prior
to 1997, when the ﬁrst Regulation on novel food came
into force. Between 1997 and 2014, there have been
around 170 applications for authorization across the EU
(7–10 applications/year). A new Novel Food regulation
for EU [Regulation (EU) 2015/2283, repealing Regulation
(EC) No. 258/97], was adopted on November 2015
(coming into effect in January 2018) and aims to
increase the efﬁciency of the authorization procedure, to
enable a quicker delivery of safe, innovative food to mar-
ket and to remove unnecessary barriers to trade, while
ensuring a high level of food safety. In EU, several
microalgae products have been already approved
according to the regulations in force, like O. auriata
(2002) and T. chuii (2014) approved as novel foods and
the oils from Schizochytrium or Ulkenia and astaxanthin
from H. pluvialis, approved as novel food ingredients.
In the United States, the FDA (Food and Drug Admin-
istration) regulates the safety of food including algal
products. According to the classiﬁcation of the Center for
Food Safety and Applied Nutrition, algal biomass is classi-
ﬁed as ‘other dietary supplement’. Spirulina, Chlorella,
Dunaliella, Haematococcus, Schizochytrium, P. cruentum
and C. cohnii are classiﬁed as food sources falling into
the GRAS (Generally Recognized As Safe) category.
Other products derived from microalgae classiﬁed by FDA
as GRAS are oils obtained from Schyzochitrium and Ulke-
nia, as well as a whole microalgal protein powder and a
lipid ingredient derived from Chlorella.
In addition to the EU and the USA, other developed
countries have speciﬁc regulations. For instance, Food
Standards Australia New Zealand (FSANZ) regulates the
use of novel food ingredients, such as products from
microalgae. According to the Food Standard Code, they
have granted permission for using the dried marine
microalga Schizochytrium, which is rich in omega-3 long-
chain polyunsaturated fatty acid (DHA), as a novel food
ingredient in a limited range of foods. Health Canada is
advising consumers to apply caution when using non-
Spirulina cyanobacterial products. In addition, it does not
allow therapeutic claims for substances sold as foods.
Market trends
In the last years, there is a growing interest of con-
sumers on ‘healthy food’ or products ‘good for you’.
Healthy food comprises food products, ingredients or
dietary supplements that may beneﬁt your overall health
or may prevent, treat or cure some diseases. Health-
conscious consumers are driving the demand for prod-
ucts that aim to promote better health, increase longevity
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and prevent the onset of chronic diseases (PriceWater-
house&Coopers, 2009). Therefore, the use of microalgal
biomass or its derived metabolites has become an inno-
vative approach for the development of healthier food
products (Gouveia et al., 2008).
Looking at the current microalgae-based products vol-
ume in the market, dried whole algae Spirulina is the lar-
gest, and more than 12 000 tons of Spirulina biomass
are produced every year (at about 30 US$/kg); nearly 70
per cent is produced in China, India and Taiwan. World-
wide, Chlorella producers cultivate an estimated 5000
tons per year. The market volume of other microalgae is
followed by D. salina (about 3000 tn for carotene),
A. ﬂosaquae (about 1500 tn for food), H. pluvialis (about
700 tn for astaxanthin), C. cohnii (500 tn of DHA) and
Shizochytrium (20 tn of DHA).
According to a recent market report published by Cre-
dence Research, the algae products market is expected
to reach US$ 44.6 Bn by 2023, expanding at a CAGR
(Compound Annual Growth Rate) of more than 5.2% from
2016 to 2023 (www.credenceresearch.com/report/algae-
products-market). For example, the global Spirulina mar-
ket is expected to register a CAGR of 10% during the fore-
cast period and is estimated to be valued at nearly US$
2000 Mn by 2026, owing to factors such as increased
application of Spirulina in cosmetics or the recent
approval of phycocyanin as natural blue colour for food.
As per Transparency Market Research, the global
nutraceutical market (including functional food and bev-
erages ingredients, dietary supplements, and personal
care and pharmaceuticals), which was valued at US$
182.60 Bn in 2015, will rise to US$ 278.96 Bn by 2021,
exhibiting a CAGR of 7.3% for this period (www.transpa
rencymarketresearch.com/pressrelease/global-nutrace
uticals-product-market.htm). Based on revenues, func-
tional food ingredients represented the largest product
segment with a share of over 31% in 2014. As the func-
tional food industry continues experienced relevant sales
growth, global food ﬁrms remain focused on the develop-
ment of new functional food and beverages with added
ingredients (Bagchi and Nair, 2017). For instance, the
Chlorella ingredients market is poised to register a
CAGR of 25.4%, to reach US$ 700 Mn by 2022.
There are also promising market niches for speciﬁc
nutraceuticals. Thus, the global market for carotenoids
is projected to reach US$ 1.7 Bn by 2022 (www.strat
egyr.com/Marketresearch/Carotenoids_Market_Trends.a
sp). Global market for both synthetic and natural
source astaxanthin in aqua feed, nutraceuticals, cos-
metics, and food and beverages is projected to reach
670 tn valued at US$ 1.1 Bn by 2020 (www.researc
handmarkets.com/reports/ 3129287/global-astaxanthin-
market-sources-technologies). In addition, as men-
tioned above, microalgae can be an alternative source
of PUFAs, which have been traditionally obtained
from ﬁsh or extracted from ﬁsh oil. EPA/DHA ingredi-
ents market size from dietary supplements application
could surpass 95 000 tn by 2022 (www.gminsights.
com/industry-analysis/EPA-DHA-omega-3-ingredients-ma
rket).
Conclusions and future prospects
Although microalgae have been used for centuries to
provide nourishment to humans and animals, only very
recently they have become much more widely cultured
and harvested at large industrial scale. Their roles in
providing health beneﬁts and nutrition as well as their
applications in the energy, and cosmetic industries are
contributing to expand their market but still several key
challenges remain to be addressed in this ﬁeld (Fig. 1).
The effects of microalgae and their nutraceutical
derived products have been tested in many nutritional
studies worldwide, but still many positive health beneﬁts
are likely to be discovered with their increased consume
as food and feed supplements. Their potential for treat-
ing and preventing many types of diseases should
improve the interest and promote research activities into
their value mainly for human health. Thus, more inten-
sive research on identifying new functional compounds
from microalgae would give more health beneﬁts to
humans. As microalgae still remain as one of the most
unexplored groups of organisms in the world, more
research in bioprospecting is needed. For instance,
microalgae can be utilized as an alternative and sustain-
able source of PUFAs; however, very few species are
used for PUFAs’ production and more in-depth investiga-
tion studies and continued isolation of new strains are
required.
Key areas that require further attention on microalgal
research are omics technologies and systems and syn-
thetic biology (Reijnders et al., 2014; Gimpel et al.,
2015; Gudmundsson and Nogales, 2015). Although
more than 30 microalgal genomes have reportedly been
sequenced (Guarnieri and Pienkos, 2015), new omics
data are necessary to understand and characterize the
pathways involved in the production of nutraceuticals
and the regulatory mechanisms that trigger the produc-
tion of these metabolites, such as nutrient deprivation,
biotic and abiotic stress. Much work is still required on
the genetic transformation and manipulation of microal-
gal strains to favour a high-level production of target
compounds.
The design and construction of large PBRs as well as
the downstream processes for harvesting and dewater-
ing the microalgal biomass and extraction and puriﬁca-
tion of target nutraceutical compounds represent the
major costs of microalgae production plants. However, in
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recent years, due to high focus of producing high
amounts of biofuels as renewable energy from microal-
gae, major improvements have been made in these
biotechnological operations. Nevertheless, more
research on the ﬁeld of constructing PBRs or open pond
systems made of inexpensive and environmentally
friendly materials and development of less energy
demanding and inexpensive downstream techniques is
required to make proﬁtable the production of natural
compounds derived from microalgae versus synthetic
ones.
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